1492 Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

1492 Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,991	Closed	-$246K	–	100
2019 Q1	$246K	Hold	13,991	–	–	0.21%	70
2018 Q4	$243K	Buy	+13,991	New	+$239K	0.22%	77
2014 Q4	–	Sell	-11,234	Closed	-$199K	–	136
2014 Q3	$199K	Sell	11,234 -444	-4%	-$8.72K	0.11%	115
2014 Q2	$241K	Buy	11,678 +340	+3%	+$6.99K	0.12%	115
2014 Q1	$247K	Hold	11,338	–	–	0.12%	114
2013 Q4	$301K	Buy	+11,338	New	+$279K	0.16%	105

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1492 Capital Management's VIVO Position: Q2 2019 in Review

1492 Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2019, closing a stake of 13,991 shares — an estimated $246K sold.

1492 Capital Management first reported a position in VIVO in Q4 2013 and held it in 6 quarters. The position peaked at $301K in Q4 2013. 173 funds tracked by Wall St. Rank hold VIVO as of Q2 2019.

1492 Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2019 after selling out during the quarter.
1492 Capital Management sold 13,991 Meridian Bioscience Inc shares in Q2 2019, an estimated $246K.
1492 Capital Management first reported a position in Meridian Bioscience Inc in Q4 2013 and held it in 6 quarters.
1492 Capital Management's Meridian Bioscience Inc position peaked at $301K in Q4 2013.
173 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2019.

Based on 1492 Capital Management's 13F filing for Q2 2019, filed 6 Aug 2019.